American Association for Cancer Research
15357163mct160459-sup-168861_3_unknown_upload_3993617_ccq43c.pdf (362.53 kB)

Supplementary Figures 1-3 from Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

Download (362.53 kB)
journal contribution
posted on 2023-04-03, 15:48 authored by Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha Jin, Stephen K. Tahir, Michael Mitten, Terry Magoc, Anahita Bhathena, Warren M. Kati, Daniel H. Albert, Yu Shen, Tamar Uziel

Suppl. Figure 1. Caspase inhibitor prevents caspase 3/7 activity; Suppl. Figure 2. Levels of BIM, BAD, BAX and BAK silencing by siRNA; Suppl. Figure 3. mRNA and protein expression of BCL2 and BCLxl upon treatment with ABBV-075.





Ten percent to 15% of all lung cancers are small-cell lung cancer (SCLC). SCLC usually grows and metastasizes before it is diagnosed and relapses rapidly upon treatment. Unfortunately, no new targeted agent has been approved in the past 30 years for patients with SCLC. The BET (bromodomain and extraterminal) proteins bind acetylated histones and recruit protein complexes to promote transcription initiation and elongation. BET proteins have been shown to regulate expression of key genes in oncogenesis, such as MYC, CCND2, and BCL2L1. Here, we demonstrate that approximately 50% of SCLC cell lines are exquisitely sensitive to growth inhibition by the BET inhibitor, ABBV-075. The majority of these SCLC cell lines underwent apoptosis in response to ABBV-075 treatment via induction of caspase-3/7 activity. ABBV-075 enhanced the expression of proapoptotic protein BIM and downregulated antiapoptotic proteins BCL2 and BCLxl to a lesser extent. Furthermore, BET inhibition increased BCL2–BIM complex, thus priming the cells for apoptosis. Indeed, strong synergy was observed both in vitro and in vivo when cotreating the cells with BET inhibitor and the BH3-mimetic, BCL2 inhibitor venetoclax (ABT-199). ABBV-075 interaction with venetoclax positively correlated with BCL2 expression. Taken together, our studies provide a rationale for treating SCLC with BET and BCL2 inhibitors in tumors with high BCL2 protein expression. Mol Cancer Ther; 16(8); 1511–20. ©2017 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager